title: An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy.
abstract: A major challenge for the management of prostate cancer (PCa) patients is to predict the clinical course of the disease after radical prostatectomy. A previous comprehensive immunohistochemical analysis using an automated image analyzer suggested that prolyl isomerase Pin1 (hence Pin1) may be a potent predictor of recurrence in PCa patients. However, a detailed pathological standard for evaluating the Pin1 immunohistochemistry in PCa has not been established yet. We here introduce a practical scoring system for Pin1 immunostaining in PCa. Using this method, the immunoreactivity of tumor cell cytoplasm and nucleus was evaluated separately and then scored for four grades (Grade=0-3). We defined the Pin1 score as the sum of both nuclear and cytoplasmic grades (Score=0-6), and the cases were then divided into either a low Pin1 score group (2) or a high Pin1 score group (3). We examined the correlation between this scoring system and postoperative PSA recurrence for 78 PCa patients. PCa patients assigned to the high Pin1 score group demonstrated PSA relapse more frequently than those assigned to the low Pin1 score group (p<0.0001). This suggests that, at the common laboratory level, our Pin1 scoring system could be a useful tool for predicting the prognosis of PCa patients after surgery.
authors.affiliation: Division of Surgical Pathology, Yokohama City University Medical Center, Urafunecho, Minami-ku, Yokohama, Kanagawa 232-0024, Japan. takesasa@yokohama-cu.ac.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sasaki
authors.forename: Akihide
authors.initials: A
authors.lastname: Ryo
authors.forename: Hiroji
authors.initials: H
authors.lastname: Uemura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Inayama
authors.forename: Shoji
authors.initials: S
authors.lastname: Yamanaka
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kubota
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nagashima
authors.forename: Masaoki
authors.initials: M
authors.lastname: Harada
authors.forename: Ichiro
authors.initials: I
authors.lastname: Aoki
mesh_terms: D002277:Carcinoma / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D000072340:NIMA-Interacting Peptidylprolyl Isomerase; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology; D009367:Neoplasm Staging; D019696:Peptidylprolyl Isomerase / Q000097:blood / Q000378:metabolism*; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology
chemical_list: D000072340:NIMA-Interacting Peptidylprolyl Isomerase; D017430:Prostate-Specific Antigen; C000606846:PIN1 protein, human; D019696:Peptidylprolyl Isomerase